The Schall Law Firm has launched an investigation into Oculis Holding AG for potential securities law violations. The investigation centers on whether the company made false or misleading statements about its Phase 3 DIAMOND trials, which Oculis had claimed were advancing as planned. On May 29, 2026, the company announced that both DIAMOND trials failed to meet their primary endpoints and that it would not pursue an FDA filing for its drug candidate. Investors who suffered losses are encouraged to contact the firm.
Oculis Holding AG Ordinary sharesInvestigation into potential securities law violations and failed Phase 3 trials leading to no FDA filing.